This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
In a series of experiments, researchers have found that an experimental MYC inhibitor drug not only targets lung cancer cells directly but also makes cancer cells easier for the immune system to target and kill.
MYC is a protein that is known to malfunction in cancer, allowing cells to grow and divide uncontrollably. However, until recently, researchers have struggled to find a way to target MYC.
The experimental drug OMO-103 was designed to inhibit MYC and is already being tested with patients in clinical trials. The new research, presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, shows that OMO-103 also seems to enable white blood cells to find and destroy cancer cells.
The research was presented by Laura Soucek, ICREA research professor, director of the Experimental Therapeutics Research Program and head of the Models of Cancer Therapies Laboratory at the Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, and co-founder and chief scientific officer of Peptomyc S.L.
Soucek said, "In this study we're looking at non-small cell lung cancer, which accounts for approximately 85% of lung cancers. Treatment for this type of cancer has changed substantially with the introduction of several new types of drugs. However, resistance remains a major problem: for many patients, their cancer does not respond to these treatments from the outset, and many cancers that initially respond eventually develop resistance.
Source link







